Lenvima (Lenvatinib)

Lenvatinib, the active ingredient in Lenvima, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is used to treat several advanced solid tumours in adult patients.

GNH USA supplies Lenvima as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenvima acts on multiple signalling pathways that drive tumour growth and angiogenesis, making it useful in several cancer types. - Differentiated thyroid cancer: inhibits tumour progression in patients with radioactive iodine‑refractory disease. - Renal cell carcinoma: slows disease advancement in advanced clear‑cell renal carcinoma. - Hepatocellular carcinoma: reduces tumour burden in unresectable liver cancer. - Endometrial carcinoma: improves progression‑free survival in advanced endometrial cancer.

Lenvima may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring. - Diarrhoea: watery stools that may be mild to moderate. - Fatigue: persistent tiredness affecting daily activities. - Nausea: feeling of sickness often managed with anti‑emetics. - Decreased appetite: reduced desire to eat, potentially leading to weight loss. - Proteinuria: presence of protein in urine detected on lab tests.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring immediate medical attention. - Arterial thromboembolic events: blood clots that can cause stroke or heart attack. - Severe haemorrhage: uncontrolled bleeding, especially gastrointestinal. - Gastro‑intestinal perforation or fistula formation. - Cardiac dysfunction: reduced heart pumping ability or arrhythmias. - Renal impairment: significant decline in kidney function.

Before initiating Lenvima, several safety considerations should be addressed. - Blood pressure monitoring: check regularly because hypertension is common. - Liver function tests: assess baseline and periodic labs to detect hepatic toxicity. - Renal function assessment: evaluate kidney health, especially in patients with pre‑existing impairment. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks; discuss with a specialist. - Drug‑specific contraindications: do not use in patients with known hypersensitivity to lenvatinib. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Lenvima can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lenvatinib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic levels. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate hypertension or electrolyte disturbances. - Other anti‑angiogenic agents: additive risk of vascular events. - CYP3A4 substrates with narrow therapeutic index (e.g., tacrolimus): monitor plasma concentrations.